Login / Signup

A new class of 5-HT1A receptor antagonists with procognitive and antidepressant properties.

Agnieszka JankowskaGrzegorz SatałaArtur ŚwierczekKrzysztof PociechaAnna PartykaMagdalena Jastrzębska-WięsekMonika Głuch-LutwinAndrzej J BojarskiElżbieta WyskaGrażyna Chłoń-Rzepa
Published in: Future medicinal chemistry (2021)
Aims: 5-HT1A receptor antagonists constitute a potential group of drugs in the treatment of CNS diseases. The aim of this study was to search for new procognitive and antidepressant drugs among amide derivatives of aminoalkanoic acids with 5-HT1A receptor antagonistic properties. Materials & methods: Thirty-three amides were designed and evaluated in silico for their drug-likeness. The synthesized compounds were tested in vitro for their 5-HT1A receptor affinity and functional profile. Moreover, their selectivity over 5-HT7, 5-HT2A and D2 receptors and ability to inhibit phosphodiesterases were evaluated. Results: A selected 5-HT1A receptor antagonist 20 (Ki = 35 nM, Kb = 4.9 nM) showed procognitive and antidepressant activity in vivo. Conclusion: Novel 5-HT1A receptor antagonists were discovered and shown as potential psychotropic drugs.
Keyphrases
  • major depressive disorder
  • photodynamic therapy
  • squamous cell carcinoma
  • emergency department
  • blood brain barrier
  • lymph node
  • molecular dynamics simulations
  • human health
  • combination therapy